Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-24
2007-04-24
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S365000, C514S374000, C514S381000, C514S414000, C546S277400, C548S235000, C548S252000, C548S467000
Reexamination Certificate
active
10486867
ABSTRACT:
The present invention relates to a β3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity
REFERENCES:
patent: 4234595 (1980-11-01), Kreighbaum et al.
patent: 4276304 (1981-06-01), Ikezaki et al.
patent: 4314943 (1982-02-01), Kreighbaum et al.
patent: 4728651 (1988-03-01), Ong et al.
patent: 4826847 (1989-05-01), Michel et al.
patent: 5808080 (1998-09-01), Bell et al.
patent: 5977154 (1999-11-01), Bell et al.
patent: 6011048 (2000-01-01), Mathvink et al.
patent: 6911463 (2005-06-01), Sall et al.
patent: 7071208 (2006-07-01), Bastian et al.
patent: 7087635 (2006-08-01), Sall et al.
patent: 2005/0020617 (2005-01-01), Bastian et al.
patent: 2006/0142327 (2006-06-01), Bastian et al.
patent: 2006/0142329 (2006-06-01), Bastian et al.
patent: 0 166 331 (1986-01-01), None
patent: 0221414 (1987-05-01), None
patent: 236624 (1987-09-01), None
patent: 611003 (1994-08-01), None
patent: 678511 (1995-10-01), None
patent: 0764640 (1997-03-01), None
patent: 827746 (1998-03-01), None
patent: 2001633 (1979-02-01), None
patent: 1549945 (1979-08-01), None
patent: WO 95/29159 (1995-11-01), None
patent: WO 97/10825 (1997-03-01), None
patent: WO 97/46556 (1997-12-01), None
patent: WO 98/4526 (1998-02-01), None
patent: WO 98/9625 (1998-03-01), None
patent: WO 98/32753 (1998-07-01), None
patent: WO 00/40560 (2000-07-01), None
patent: WO 00/44721 (2000-08-01), None
patent: WO 01/7026 (2001-02-01), None
patent: WO 01/35947 (2001-05-01), None
patent: WO 01/36412 (2001-05-01), None
patent: WO 01/53298 (2001-07-01), None
patent: WO 020676 (2002-01-01), None
patent: WO 02/38543 (2002-05-01), None
patent: WO 03/16276 (2003-02-01), None
patent: WO 03/16307 (2003-02-01), None
Weber, A.E., et al., “3-Pyridyloxypropanlamine agonists of the beta3 adrenergic receptor with improved pharmacokinetic properties”Bioorganic&Medicinal Chemistry Letters,Aug. 18, 1998, vol. 8, No. 16, pp. 2111-2116.
Lee, et al., J.Het.Chem., 32(1):1-11, 1995.
Mathvink, Bioorganic & Medicinal Chemistry Letters, 9(13):1869-1874, 1999.
Shuker A J, et al;Tetrahedron Letters;38(35):6149-6152, 1997.
Weber, et al; Bioorganic & Medicinal Chemistry Letters; 8(9):1101-1106, 1998.
Bastian Jolie Anne
Evers Britta
Finley Don Richard
He John Xiaoqiang
Jesudason Cynthia Darshini
Demeter John C.
Eli Lilly and Company
Freistein Andrew B.
McKane Joseph K.
Voy Gil T.
LandOfFree
β3 adrenergic agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with β3 adrenergic agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β3 adrenergic agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3758987